What is Atom Bioscience and Pharmaceutical?
Atom Bioscience and Pharmaceutical is a research-driven entity dedicated to the discovery and development of novel therapeutic treatments for metabolic diseases and cancers. Established in 2012 and headquartered in Jiangsu, China, the company leverages its scientific expertise to address critical unmet medical needs. Its focus on complex diseases positions it within a highly competitive yet vital segment of the global pharmaceutical market, aiming to translate cutting-edge research into viable drug candidates.
How much funding has Atom Bioscience and Pharmaceutical raised?
Atom Bioscience and Pharmaceutical has raised a total of $97M across 3 funding rounds:
Series A
$22M
Series B
$30M
Series C
$45M
Series A (2018): $22M, investors not publicly disclosed
Series B (2020): $30M led by Livzon Pharmaceutical Group and Sequoia Capital China
Series C (2022): $45M supported by EFung Capital, ShenZen GTJA Investment Group, Suzhou Oriza Holdings, and Xicheng Jinrui Equity Investment Fund
Key Investors in Atom Bioscience and Pharmaceutical
EFung Capital
EFung Capital is a life science venture capital firm established in 1996, focusing on investments in clinical-stage pharmaceutical and medical device companies. Their strategic backing of Atom Bioscience indicates a focus on companies with advanced therapeutic development.
ShenZen GTJA Investment Group
ShenZen GTJA Investment Group is an entity involved in the company's funding rounds. Further details on their specific investment focus are not publicly available.
Suzhou Oriza Holdings
Suzhou Oriza Holdings is a participant in Atom Bioscience's funding rounds. Their involvement suggests a strategic interest in the company's growth and development within the pharmaceutical sector.
What's next for Atom Bioscience and Pharmaceutical?
The recent major enterprise-level funding positions Atom Bioscience and Pharmaceutical for accelerated growth and pipeline expansion. This capital infusion is expected to fuel further research and development initiatives, potentially advancing existing drug candidates through clinical trials and exploring new therapeutic avenues. The strategic nature of the investment suggests a strong confidence from backers in the company's long-term vision and its capacity to achieve significant milestones in drug development, reinforcing its trajectory towards becoming a key player in its specialized therapeutic areas.
See full Atom Bioscience and Pharmaceutical company page
